Your new experience awaits. Try the new design now and help us make it even better

ORIGINAL RESEARCH article

Front. Oncol.

Sec. Head and Neck Cancer

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1683501

This article is part of the Research TopicData and Precision: AI Leading the Revolution in Immunoradiotherapy for Advanced Malignant TumorsView all articles

Prediction of Prognosis in T4 or N3 Locally Advanced Nasopharyngeal Carcinoma Receiving Chemoradiotherapy Using Machine Learning Methods

Provisionally accepted
政  马政 马1Weijie  LiuWeijie Liu2Xiaoya  LuoXiaoya Luo1Xinran  NiuXinran Niu3Yanmei  LiYanmei Li3Yuanling  MaYuanling Ma3Li  HouLi Hou1*
  • 1General Hospital of Ningxia Medical University, Yinchuan, China
  • 2Peking University First Hospital Ningxia Women and Children's Hospital, Yinchuan, China
  • 3Ningxia Medical University, Yinchuan, China

The final, formatted version of the article will be published soon.

Background: This study aims to develop and validate a survival prediction model for T4 or N3 locally advanced nasopharyngeal carcinoma (NPC) patients undergoing chemoradiotherapy (CRT) using machine learning methods. Methods: A total of 293 patients with locally advanced NPC (T4 or N3 stage) treated with CRT were included in the study. The cohort was divided into a training set (173 patients) and a validation set (120 patients). LASSO regression was used to identify significant prognostic factors, and Cox regression analysis was performed to assess the independent impact of these factors on progression-free survival (PFS). A nomogram was constructed based on the identified prognostic factors to predict 1-, 2-, and 3-year PFS. Model performance was validated using ROC curves, calibration curves, and decision curve analysis (DCA). Results: The training cohort showed 1-, 2-, and 3-year PFS rates of 92.4%, 81.3%, and 75.2%, respectively. In the validation cohort, the 1-, 2-, and 3-year PFS rates were 90.1%, 83.5%, and 76.0%, respectively, with no significant differences between the groups (P=0.94). The LASSO-Cox model identified N stage and Epstein-Barr virus (EBV) levels as key prognostic factors. The nomogram demonstrated good discrimination with AUC values of 0.802, 0.709, and 0.686 at 1, 2, and 3 years, respectively. The ROC curve shows the model's performance with AUC values at 1 year (0.802), 2 years (0.709), and 3 years (0.686), demonstrating the model's ability to distinguish between different survival outcomes. The calibration curves and DCA confirmed the model's good agreement with observed outcomes and its clinical net benefit across different risk thresholds. Conclusion: The survival prediction model based on LASSO and Cox regression provides a robust and interpretable tool for predicting PFS in patients with T4 or N3 locally advanced NPC undergoing CRT.

Keywords: prediction, Nasopharygeal carcinoma, chemotherapy, Radiation, Maching learning

Received: 19 Aug 2025; Accepted: 29 Sep 2025.

Copyright: © 2025 马, Liu, Luo, Niu, Li, Ma and Hou. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Li Hou, hlahl99@sina.com

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.